Closing the HIV Diagnosis Gap in Germany with Gilead Sciences
Gilead Sciences is partnering with local German organizations to close the HIV diagnosis gap, particularly in rural and migrant communities. Germany has achieved 90% diagnosis and treatment rates for people living with HIV, but aims to reach the UNAIDS goal of 95% by 2025. Gilead's HIVISION100 initiative brings together 45 HIV experts to share best practices and improve testing accessibility.
One key partner, AIDS-Hilfe Krefeld, utilizes a mobile clinic to offer HIV and STI testing in resource- areas. Anja Wiese, an educator for the organization, believes that collaborative efforts can help Germany achieve 100% diagnosis rates. Gilead's innovations have transformed HIV from a fatal disease to a chronic and preventable condition for many, and the company is now focused on helping end the HIV epidemic globally.
Gilead Sciences sta collaborando con organizzazioni locali in Germania per ridurre il divario nella diagnosi dell'HIV, in particolare nelle comunità rurali e migranti. La Germania ha raggiunto tassi di diagnosi e trattamento del 90% per le persone che vivono con l'HIV, ma punta a raggiungere l'obiettivo dell'UNAIDS del 95% entro il 2025. L'iniziativa HIVISION100 di Gilead riunisce 45 esperti di HIV per condividere le migliori pratiche e migliorare l'accessibilità ai test.
Un partner chiave, AIDS-Hilfe Krefeld, utilizza una clinica mobile per offrire test HIV e STI in aree con poche risorse. Anja Wiese, un'educatrice dell'organizzazione, crede che sforzi collaborativi possano aiutare la Germania a raggiungere tassi di diagnosi del 100%. Le innovazioni di Gilead hanno trasformato l'HIV da una malattia fatale a una condizione cronica e prevenibile per molti, e ora l'azienda si concentra sull'aiutare a porre fine all'epidemia di HIV a livello globale.
Gilead Sciences se está asociando con organizaciones locales en Alemania para cerrar la brecha en el diagnóstico del VIH, particularmente en comunidades rurales y migrantes. Alemania ha logrado tasas de diagnóstico y tratamiento del 90% para las personas que viven con el VIH, pero tiene como objetivo alcanzar la meta del 95% de ONUSIDA para 2025. La iniciativa HIVISION100 de Gilead reúne a 45 expertos en VIH para compartir las mejores prácticas y mejorar el acceso a las pruebas.
Un socio clave, AIDS-Hilfe Krefeld, utiliza una clínica móvil para ofrecer pruebas de VIH y ETS en áreas con recursos limitados. Anja Wiese, educadora de la organización, cree que los esfuerzos colaborativos pueden ayudar a Alemania a alcanzar tasas de diagnóstico del 100%. Las innovaciones de Gilead han transformado el VIH de una enfermedad fatal a una condición crónica y prevenible para muchos, y la compañía ahora se centra en ayudar a poner fin a la epidemia de VIH a nivel mundial.
길리아드 사이언스는 독일의 지역 단체들과 협력하여 HIV 진단 격차를 해소하고 있으며, 특히 농촌 및 이민자 커뮤니티를 대상으로 하고 있습니다. 독일은 HIV에 감염된 사람들의 진단 및 치료 비율이 90%에 이르렀지만, 2025년까지 UNAIDS 목표인 95%에 도달하는 것을 목표로 하고 있습니다. 길리아드의 HIVISION100 이니셔티브는 45명의 HIV 전문가를 모아 최선의 사례를 공유하고 검사 접근성을 개선하고 있습니다.
핵심 파트너인 AIDS-Hilfe Krefeld는 자원이 부족한 지역에서 HIV 및 성병 검사를 제공하기 위해 이동 클리닉을 활용합니다. 이 조직의 교육자인 안야 비제는 협력적 노력이 독일이 100% 진단 비율을 달성하는 데 도움이 될 수 있다고 믿고 있습니다. 길리아드의 혁신은 많은 사람들에게 HIV를 치명적인 질병에서 만성적이고 예방 가능한 상태로 변화시켰으며, 이제 이 회사는 전 세계적으로 HIV 유행을 끝내는 데 주력하고 있습니다.
Gilead Sciences s'associe à des organisations locales allemandes pour combler le fossé du diagnostic du VIH, en particulier dans les communautés rurales et migrantes. L'Allemagne a atteint un taux de diagnostic et de traitement de 90 % pour les personnes vivant avec le VIH, mais vise à atteindre l'objectif de 95 % de l'ONUSIDA d'ici 2025. L'initiative HIVISION100 de Gilead rassemble 45 experts en VIH pour partager les meilleures pratiques et améliorer l'accessibilité des tests.
Un partenaire clé, AIDS-Hilfe Krefeld, utilise une clinique mobile pour offrir des tests VIH et IST dans des zones à faibles ressources. Anja Wiese, éducatrice pour l'organisation, estime que des efforts collaboratifs peuvent aider l'Allemagne à atteindre un taux de diagnostic de 100 %. Les innovations de Gilead ont transformé le VIH d'une maladie mortelle en une condition chronique et évitable pour beaucoup, et l'entreprise se concentre désormais sur l'aide à l'éradication de l'épidémie de VIH à l'échelle mondiale.
Gilead Sciences arbeitet mit lokalen deutschen Organisationen zusammen, um die HIV-Diagnoselücke zu schließen, insbesondere in ländlichen und migrantischen Gemeinschaften. Deutschland hat eine Diagnose- und Behandlungsrate von 90% für Menschen, die mit HIV leben, erreicht, strebt aber an, bis 2025 das UNAIDS-Ziel von 95% zu erreichen. Die HIVISION100-Initiative von Gilead vereint 45 HIV-Experten, um bewährte Praktiken auszutauschen und die Testzugänglichkeit zu verbessern.
Ein wichtiger Partner, AIDS-Hilfe Krefeld, nutzt eine mobile Klinik, um HIV- und STI-Tests in ressourcenarmen Gebieten anzubieten. Anja Wiese, eine Pädagogin der Organisation, ist überzeugt, dass gemeinschaftliche Anstrengungen Deutschland helfen können, eine Diagnosequote von 100% zu erreichen. Die Innovationen von Gilead haben HIV von einer tödlichen Krankheit in eine chronische und vermeidbare Erkrankung für viele verwandelt, und das Unternehmen konzentriert sich nun darauf, die HIV-Epidemie weltweit zu beenden.
- Gilead Sciences is actively partnering with local organizations to improve HIV diagnosis rates in Germany
- The company launched the HIVISION100 initiative to help Germany reach the 95% HIV diagnosis goal set by UNAIDS for 2025
- Gilead's innovations have helped transform HIV from a fatal disease to a chronic and preventable condition for many
- None.
NORTHAMPTON, MA / ACCESSWIRE / August 8, 2024 / Gilead Sciences
As a nation where
Early diagnosis is essential to help end the HIV epidemic, which is why Gilead partners with numerous local German organizations. Among them is AIDS-Hilfe Krefeld, whose outreach efforts include utilizing a mobile clinic to test people in resource-limited areas where there are remaining needs and gaps in care.
"We travel to rural areas and offer local HIV and STI testing to people who can't find their way to us, and we try to help people get treatment," says Anja Wiese, an educator for AIDS-Hilfe Krefeld.
Working Together Towards
Gilead's innovations have helped transform HIV from a fatal disease to a chronic and preventable disease for many, and it now has its sights set on helping to end the HIV epidemic. In order to help Germany achieve the
HIV leaders like Anja believe Germany and other countries around the world can help close the gap if organizations pull together to utilize the strategies unveiled in the initiative. "I think that we can definitely achieve
Watch the video above to learn about the ongoing efforts underway in Germany to close the diagnosis gap.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on accesswire.com
FAQ
What is Gilead Sciences' HIVISION100 initiative in Germany?
How is Gilead Sciences (GILD) addressing HIV diagnosis gaps in rural German communities?
What is the current HIV diagnosis rate in Germany as of 2024?
How has Gilead Sciences (GILD) contributed to HIV treatment advancements?
